Drug Profile
Research programme: antibacterials - Nemesis Bioscience
Alternative Names: Nemesis SymbioticsLatest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Nemesis Bioscience
- Class Antibacterials; Gene therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Bacterial infections in United Kingdom (PO)
- 03 Oct 2023 Discontinued - Preclinical for Bacterial infections in United Kingdom (Topical)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom (PO)